[go: up one dir, main page]

PE20011074A1 - Uso de pramipexol en el tratamiento de trastornos de adiccion - Google Patents

Uso de pramipexol en el tratamiento de trastornos de adiccion

Info

Publication number
PE20011074A1
PE20011074A1 PE2001000131A PE2001000131A PE20011074A1 PE 20011074 A1 PE20011074 A1 PE 20011074A1 PE 2001000131 A PE2001000131 A PE 2001000131A PE 2001000131 A PE2001000131 A PE 2001000131A PE 20011074 A1 PE20011074 A1 PE 20011074A1
Authority
PE
Peru
Prior art keywords
pramipexol
treatment
day
addiction
disorders
Prior art date
Application number
PE2001000131A
Other languages
English (en)
Inventor
Wong Eric Ho Fong
Voigtlander Philip F Von
Robert Clyde Marshall
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22676121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20011074(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of PE20011074A1 publication Critical patent/PE20011074A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE AL USO DE PRAMIPEXOL (2-AMINO-6-n-PROPILAMINO-4,5,6,7-TETRAHIDRO-BENZOTIAZOL PARA EL TRATAMIENTO DE TRASTORNOS DE ADICCION, POR EL USO DE SUSTANCIAS PSICOACTIVAS, TRASTORNOS DE INTOXICACION, TRASTORNO DE INHALACION, ADICCION AL ALCOHOL, TABACO, NICOTINA; UTILIZANDOSE DE 0,01mg/DIA A 10mg/DIA; O SE INICIA CON 0,125 mg ADMINISTRANDO AL PACIENTE 3 VECES AL DIA Y DESPUES SE AUMENTA GRADUALMENTE A CONCENTRACIONES MAYORES DE 5-7 DIAS HASTA ALCANZAR EL EFECTO TERAPEUTICO
PE2001000131A 2000-02-23 2001-02-07 Uso de pramipexol en el tratamiento de trastornos de adiccion PE20011074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18424200P 2000-02-23 2000-02-23

Publications (1)

Publication Number Publication Date
PE20011074A1 true PE20011074A1 (es) 2001-10-04

Family

ID=22676121

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000131A PE20011074A1 (es) 2000-02-23 2001-02-07 Uso de pramipexol en el tratamiento de trastornos de adiccion

Country Status (24)

Country Link
US (1) US6410579B2 (es)
EP (1) EP1257271B1 (es)
JP (1) JP2003523387A (es)
KR (1) KR20030016230A (es)
CN (1) CN1396826A (es)
AR (1) AR027945A1 (es)
AT (1) ATE326967T1 (es)
AU (1) AU781358B2 (es)
BR (1) BR0107983A (es)
CA (1) CA2397874A1 (es)
CO (1) CO5261586A1 (es)
DE (1) DE60119896T2 (es)
DK (1) DK1257271T3 (es)
ES (1) ES2263586T3 (es)
HK (1) HK1053058A1 (es)
MX (1) MXPA02008184A (es)
MY (1) MY127739A (es)
NZ (1) NZ520974A (es)
PE (1) PE20011074A1 (es)
PT (1) PT1257271E (es)
SI (1) SI1257271T1 (es)
TW (1) TWI250016B (es)
WO (1) WO2001062249A1 (es)
ZA (1) ZA200206119B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
AU2002360600B2 (en) 2001-12-11 2007-11-29 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
PA8578501A1 (es) * 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
RU2252790C1 (ru) * 2004-01-12 2005-05-27 Семенов Сергей Петрович Способ первичной психопрофилактики наркомании среди учащихся 13-15 лет
RU2252789C1 (ru) * 2004-01-12 2005-05-27 Семенов Сергей Петрович Способ первичной психопрофилактики наркомании среди студентов высших учебных заведений
JP2007518754A (ja) * 2004-01-22 2007-07-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング モノアミン神経伝達物質再取込みインヒビターとドーパミンアゴニストを含む医薬組成物
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
ES2355735T5 (es) * 2004-08-13 2014-06-27 Boehringer Ingelheim International Gmbh Formulación en comprimidos de liberación extendida que contiene pramipexol o una de sus sales farmac�uticamente aceptables, método para su fabricación y su uso
EP2431026A1 (en) * 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
EP1988875A2 (en) * 2006-02-10 2008-11-12 Boehringer Ingelheim International GmbH Modified release formulation
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2137171A4 (en) 2007-03-14 2010-05-19 Knopp Neurosciences Inc SYNTHESIS OF BENZOTHIAZOLE DIAMINES SUBSTITUTED AND PURIFIED FROM THE CHIRAL PERSPECTIVE
EP2203448B1 (de) * 2007-09-21 2011-06-22 Sanofi-Aventis Phenothiazin-derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CA2734491A1 (en) 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
DE102012108398B4 (de) 2012-09-10 2014-05-22 Schott Ag Kochfeld, Blende, Geräteeinhausung sowie Kamin- oder Ofensichtscheibe mit einem Hologramm und Verfahren zu dessen bzw. deren Herstellung, sowie Verwendung eines Substrats, auf welchem ein Phasenhologramm aufgebracht ist
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
SMT202100119T1 (it) 2013-07-12 2021-05-07 Knopp Biosciences Llc Trattamento dei livelli elevati di eosinofili e/o basofili
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0186087B1 (de) 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel
DE3843227A1 (de) 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
DE3930282A1 (de) 1989-09-11 1991-03-21 Boehringer Ingelheim Kg Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit
DE3933738A1 (de) 1989-10-10 1991-04-11 Boehringer Ingelheim Kg Neue verwendung von 2-aminothiazol-derivaten (tsh)
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DE4241013A1 (de) 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
US5650420A (en) 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6001861A (en) 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
CA2384840A1 (en) * 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for cocaine craving

Also Published As

Publication number Publication date
JP2003523387A (ja) 2003-08-05
AU781358B2 (en) 2005-05-19
AU3445401A (en) 2001-09-03
WO2001062249A1 (en) 2001-08-30
EP1257271B1 (en) 2006-05-24
HK1053058A1 (zh) 2003-10-10
CO5261586A1 (es) 2003-03-31
SI1257271T1 (sl) 2006-10-31
AR027945A1 (es) 2003-04-16
DE60119896D1 (de) 2006-06-29
US20010041727A1 (en) 2001-11-15
ZA200206119B (en) 2003-10-31
BR0107983A (pt) 2003-01-28
NZ520974A (en) 2004-04-30
MXPA02008184A (es) 2002-11-29
MY127739A (en) 2006-12-29
ES2263586T3 (es) 2006-12-16
KR20030016230A (ko) 2003-02-26
US6410579B2 (en) 2002-06-25
EP1257271A1 (en) 2002-11-20
TWI250016B (en) 2006-03-01
CA2397874A1 (en) 2001-08-30
CN1396826A (zh) 2003-02-12
DK1257271T3 (da) 2006-08-21
ATE326967T1 (de) 2006-06-15
PT1257271E (pt) 2006-09-29
DE60119896T2 (de) 2006-11-09

Similar Documents

Publication Publication Date Title
PE20011074A1 (es) Uso de pramipexol en el tratamiento de trastornos de adiccion
EA200601799A1 (ru) Гидразидсодержащие соединения - ингибиторы cftr и их применение
AR063782A1 (es) Parche y metodo transdermico para emesis
DE59401401D1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
BR0314271A (pt) Forma de dosagem oral sólida útil para administração oral transmucosal, e, métodos de reduzir apetências por nicotina, e, uso de tabaco
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
IL156798A0 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependency
SE0000601D0 (sv) Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
HUP0301828A2 (hu) Apomorfin alkalmazása nemi mżködészavar meghatározott apomorfin-plazmakoncentrációval történż kezelésre szolgáló készítmények elżállítására
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
BRPI0409380A (pt) composições farmacêuticas
ATE301462T1 (de) Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden
AR027937A1 (es) Tratamiento de condiciones alergicas e inflamatorias
ATE350024T1 (de) Flüssige zubereitung enthaltend tobramycin
BR0306798A (pt) Uso de melagatran ou de um derivado farmaceuticamente aceitável deste, métodos de tratamento de diabetes mellitus tipo i, de transplante de células de enxertamento de ilhotas de langerhans, para melhorar a independência de insulina em pacientes com diabetes mellitus tipo i, e de tratamento de reação inflamatória mediada pelo sangue instantânea, formulação farmacêutica para uso no tratamento de diabetes mellitus tipo i, kit de partes, e, método de fabricação de um kit de partes.
RU2008148334A (ru) Водный экстракт листьев табака и его применение при лечении зависимости
Sukhov et al. Long-term intranasal insulin administration improves spatial memory in male rats with prolonged type 1 diabetes mellitus and in healthy rats
ES2173977T3 (es) Uso de r-(z)-alfa-(metoxiimino)-alfa-(1-azabiciclo(2.2.2)oct-3-il)acetonitrilo para reducir la formacion de la proteina amilacea beta a4 en la enfermedad de alzheimer.
BR0112939A (pt) Compostos para o tratamento de distúrbios de dependência
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
AR020815A1 (es) Procedimiento para el tratamiento de la esquizofrenia, como tambien medios para ser utilizados en dicho procedimiento
DE602004025040D1 (de) Den blutzuckerspiegel bei diabetes mellitus regulierendes tetrapeptid
BR0015024A (pt) Aplicação de carbinóis substituìdos por 2-imidazolila para a preparação de um medicamento para o tratamento ou profilaxia de doenças provocadas por estados isquêmicos
BR0211323A (pt) Combinação de ingredientes ativos, uso de uma combinação de ingredientes ativos e método de terapia farmacológica de dependência de nicotina
ATE403424T1 (de) Verwendung von zinkgluconat zur behandlung von hydradenitis suppurativa

Legal Events

Date Code Title Description
FC Refusal